Advertisement

Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction

      Animal experimental data have shown that lipid-lowering agents reduce myocardial infarct size. This association has not been well studied in humans. We compared infarct size in 10,548 patients in the GUSTO IIb and PURSUIT trials who were (n = 1,028) or were not (n = 9,520) on lipid-lowering therapy before an enrolling myocardial infarction (MI). Patients using lipid-lowering agents before their index MI had smaller infarcts than those who were not using these agents (median peak creatine kinase [CK]-MB 4.2 vs 5.2 times the upper limit of normal [ULN]; p <0.0001). Similarly, in an unadjusted model, patients on previous lipid-lowering therapy were less likely to have a peak CK-MB >3 times the ULN (620 of 1,028 [60.3%] vs 6,486 of 9,520 patients [68.1%]; p <0.001; relative risk 0.88, 95% confidence interval 0.84 to 0.93, p <0.0001). In a covariate- and propensity-adjusted multivariable model, the association between pretreatment with lipid-lowering agents and smaller infarct size persisted (relative risk for CK-MB >3 times the ULN 0.94, 95% confidence interval 0.88 to 0.99, p = 0.04). In conclusion, patients on lipid-lowering agents before an MI had significantly smaller infarcts. These findings suggest that lipid-lowering therapy may exert additional salutary effects in the setting of acute coronary syndromes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • The GUSTO IIb Investigators
        A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.
        N Engl J Med. 1996; 335: 775-782
        • The PURSUIT Trial Investigators
        Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
        N Engl J Med. 1998; 339: 436-443
        • Hackel D.B.
        • Reimer K.A.
        • Ideker R.E.
        • Mikat E.M.
        • Hartwell T.D.
        • Parker C.B.
        • Braunwald E.B.
        • Buja M.
        • Gold H.K.
        • Jaffe A.S.
        • et al.
        Comparison of enzymatic and anatomic estimates of myocardial infarct size in man.
        Circulation. 1984; 70: 824-835
        • Licka M.
        • Zimmermann R.
        • Zehelein J.
        • Dengler T.J.
        • Katus H.A.
        • Kubler W.
        Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size.
        Heart. 2002; 87: 520-524
        • Roberts R.
        • Ambos H.D.
        • Sobel B.E.
        Estimation of infarct size with MB rather than total CK.
        Int J Cardiol. 1983; 2: 479-492
        • Rubin D.B.
        Estimating causal effects from large data sets using propensity scores.
        Ann Intern Med. 1997; 127: 757-763
        • Joffe M.M.
        • Rosenbaum P.R.
        Invited commentary: propensity scores.
        Am J Epidemiol. 1999; 150: 327-333
        • Austin P.C.
        • Mamdani M.M.
        A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use.
        Stat Med. 2006; 25: 2084-2106
        • Jones S.P.
        • Gibson M.F.
        • Rimmer III, D.M.
        • Gibson T.M.
        • Sharp B.R.
        • Lefer D.J.
        Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
        J Am Coll Cardiol. 2002; 40: 1172-1178
        • Wolfrum S.
        • Dendorfer A.
        • Schutt M.
        • Weidtmann B.
        • Heep A.
        • Tempel K.
        • Klein H.H.
        • Dominiak P.
        • Richardt G.
        Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway.
        J Cardiovasc Pharmacol. 2004; 44: 348-355
        • Bybee K.A.
        • Kopecky S.L.
        • Williams B.A.
        • Murphy J.G.
        • Scott Wright R.
        Reduced creatine kinase release with statin use at the time of myocardial infarction.
        Int J Cardiol. 2004; 96: 461-466
        • Hoffmann R.
        • Haager P.
        • Suliman H.
        • Christott P.
        • Radke P.
        • Blindt R.
        • Kelm M.
        Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion.
        Am J Cardiol. 2008; 101: 139-143
        • Spencer F.A.
        • Fonarow G.C.
        • Frederick P.D.
        • Wright R.S.
        • Every N.
        • Goldberg R.J.
        • Gore J.M.
        • Dong W.
        • Becker R.C.
        • French W.
        Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction.
        Arch Intern Med. 2004; 164: 2162-2168
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • Ganz P.
        • Oliver M.F.
        • Waters D.
        • Zeiher A.
        • Chaitman B.R.
        • Leslie S.
        • Stern T.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • Aronow H.D.
        • Topol E.J.
        • Roe M.T.
        • Houghtaling P.L.
        • Wolski K.E.
        • Lincoff A.M.
        • Harrington R.A.
        • Califf R.M.
        • Ohman E.M.
        • Kleiman N.S.
        • et al.
        Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
        Lancet. 2001; 357: 1063-1068
        • Laufs U.
        • Endres M.
        • Custodis F.
        • Gertz K.
        • Nickenig G.
        • Liao J.K.
        • Bohm M.
        Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.
        Circulation. 2000; 102: 3104-3110
        • Seljeflot I.
        • Tonstad S.
        • Hjermann I.
        • Arnesen H.
        Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
        Thromb Res. 2002; 105: 285-290
        • Hoshida S.
        • Nishida M.
        • Yamashita N.
        • Igarashi J.
        • Hori M.
        • Kamada T.
        • Kuzuya T.
        • Tada M.
        Amelioration of severity of myocardial injury by a nitric oxide donor in rabbits fed a cholesterol-rich diet.
        J Am Coll Cardiol. 1996; 27: 902-909
        • Hoshida S.
        • Yamashita N.
        • Otsu K.
        • Kuzuya T.
        • Hori M.
        Cholesterol feeding exacerbates myocardial injury in Zucker diabetic fatty rats.
        Am J Physiol Heart Circ Physiol. 2000; 278: H256-H262
        • Bulhak A.A.
        • Gourine A.V.
        • Gonon A.T.
        • Sjoquist P.O.
        • Valen G.
        • Pernow J.
        Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
        Acta Physiol Scand. 2005; 183: 151-159
        • Blanco M.
        • Nombela F.
        • Castellanos M.
        • Rodriguez-Yanez M.
        • Garcia-Gil M.
        • Leira R.
        • Lizasoain I.
        • Serena J.
        • Vivancos J.
        • Moro M.A.
        • Davalos A.
        • Castillo J.
        Statin treatment withdrawal in ischemic stroke: a controlled randomized study.
        Neurology. 2007; 69: 904-910
        • Spencer F.A.
        • Goldberg R.J.
        • Gore J.M.
        • Fox K.A.
        • Avezum A.
        • Agnelli G.
        • Kritharides L.
        • Anderson F.A.
        • Goodman S.G.
        • FitzGerald G.
        • Allegrone J.
        • Brieger D.
        Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein > or = 100 mg/dl versus <100 mg/dl.
        Am J Cardiol. 2007; 100: 913-918
        • Kiortsis D.N.
        • Giral P.
        • Bruckert E.
        • Turpin G.
        Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients.
        J Clin Pharm Ther. 2000; 25: 445-451
        • Simons L.A.
        • Levis G.
        • Simons J.
        Apparent discontinuation rates in patients prescribed lipid-lowering drugs.
        Med J Aust. 1996; 164: 208-211
        • de Lemos J.A.
        • Blazing M.A.
        • Wiviott S.D.
        • Lewis E.F.
        • Fox K.A.
        • White H.D.
        • Rouleau J.L.
        • Pedersen T.R.
        • Gardner L.H.
        • Mukherjee R.
        • et al.
        Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
        JAMA. 2004; 292: 1307-1316
        • Siegel D.
        • Lopez J.
        • Meier J.
        Use of cholesterol-lowering medications in the United States from 1991 to 1997.
        Am J Med. 2000; 108: 496-499
        • EUROASPIRE Study Group
        EUROASPIRE.
        Eur Heart J. 1997; 18: 1569-1582
        • Rubins H.B.
        • Robins S.J.
        • Collins D.
        • Fye C.L.
        • Anderson J.W.
        • Elam M.B.
        • Faas F.H.
        • Linares E.
        • Schaefer E.J.
        • Schectman G.
        • Wilt T.J.
        • Wittes J.
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
        N Engl J Med. 1999; 341: 410-418